28.04.2023 • News

Siegfried Breaks Ground for Global R&D Center

Swiss-based, globally oriented CDMO Siegfried has broken ground or its new global Research and Development (R&D) Center for Drug Substances at its site in Evionnaz, Switzerland, which the company describes as a “key pillar” in its related network.

From left: Sophia Dini (State Council Delegate for Economy and Innovation),...
From left: Sophia Dini (State Council Delegate for Economy and Innovation), Beat Rieder (Council of State VS, Die Mitte), Valerie Santacrocce-Tachini (President of the municipality Evionnaz), Wolfgang Wienand (CEO Siegfried), Marcel Signer (Site Head Siegfried Evionnaz), Irene Wosgien (COO DS Siegfried), Jürgen Roos (CSO Siegfried), Andreas Casutt (VRP Siegfried) © Siegfried

The new center, costing as much as 25 million Swiss francs to build, is set to begin operations in 2024 with 100 “highly skilled specialists.” Together with the research center at its home base in zofingen, Siegfried said the new facility will “significantly increase R&D capacity to drive future growth.“

With its advanced chemical and analytical facilities and state-of-the-art laboratories, the center will offer chemical process R&D and analytical development services for the entire drug substances network. CEO Wolfgang Wienand said the facility center will not only strengthen its site in Evionnaz, but also its global network.  

Author: Dede Williams, Freelance Journalist

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

most read